251. Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons.
- Author
-
Liu DZ, Cheng XY, Ander BP, Xu H, Davis RR, Gregg JP, and Sharp FR
- Subjects
- Animals, Cell Cycle drug effects, Cell Differentiation drug effects, Cell Differentiation physiology, Cells, Cultured, Corpus Striatum drug effects, Male, Neurons drug effects, Protein Kinase Inhibitors pharmacology, Rats, Rats, Sprague-Dawley, src-Family Kinases metabolism, Cell Cycle physiology, Corpus Striatum enzymology, Corpus Striatum pathology, Neurons enzymology, Neurons pathology, Thrombin toxicity, src-Family Kinases antagonists & inhibitors
- Abstract
Since Src kinase inhibitors decrease brain injury produced by intracerebral hemorrhage (ICH) and thrombin is activated following ICH, this study determined whether Src kinase inhibitors decrease thrombin-induced brain injury. Thrombin injections into adult rat striatum produced focal infarction and motor deficits. The Src kinase inhibitor PP2 decreased thrombin-induced Src activation, infarction in striatum and motor deficits in vivo. Thrombin applied to cultured post-mitotic striatal neurons caused: injury to axons and dendrites; many TUNEL positive neuronal nuclei; and re-entry into the cell cycle as manifested by cyclin D1 expression, induction of several other cell cycle genes and cyclin-dependent kinase 4 activation. PP2 dose-dependently attenuated thrombin-induced injury to the cultured neurons; and attenuated thrombin-induced neuronal cell cycle re-entry. These results are consistent with the hypotheses that Src kinase inhibitors decrease injury produced by ICH by decreasing thrombin activation of Src kinases and, at least in part, by decreasing Src induced cell cycle re-entry.
- Published
- 2008
- Full Text
- View/download PDF